Loading...

JCR Pharmaceuticals Co., Ltd.

4552.TJPX
HealthcareDrug Manufacturers - General
¥570.00
¥-20.00(-3.39%)

JCR Pharmaceuticals Co., Ltd. (4552.T) Stock Overview

Explore JCR Pharmaceuticals Co., Ltd.’s financial performance, market position, analyst ratings, and future outlook.

Revenue Growth
24.83%
24.83%
Profit Growth
¥-38.45
46.00%
EPS Growth
¥-38.45
45.45%
Operating Margin
-20.90%
51.40%
ROE
-8.99%
46.00%
Dividend Yield
0.00%
9.08%
Analyst Recommendations data is not available for 4552.TAnalyst Recommendations details for 4552.T are currently unavailable. We're actively monitoring for updates and will publish them as soon as they’re released. Please check back again shortly.

Company Profile

JCR Pharmaceuticals Co., Ltd., a specialty pharmaceuticals company, engages in the research, development, manufacture, import and export, and sale of pharmaceutical products, regenerative medicines, and drug substances in Japan. It offers various therapeutic products, including GROWJECT used for the treatment of growth hormone deficiency and short stature; IZCARGO to treat Mucopolysaccharidosis type II; Agalsidase Beta BS I.V. Infusion used for the treatment of Fabry disease; and TEMCELL HS Inj used to treat acute graft-versus-host disease. The company also develops Epoetin Alfa BS and Darbepoetin Alfa BS Injections for the treatment of renal anemia. In addition, it sells medical devices and laboratory instruments. JCR Pharmaceuticals Co., Ltd. was incorporated in 1975 and is headquartered in Ashiya, Japan.

CEO

Mr. Shin Ashida

Employees

934

Headquarters

3-19 Kasuga-cho, Ashiya

Founded

2005

Frequently Asked Questions